A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy

NCT04640623 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

220

Enrollment

INDUSTRY

Sponsor class

Conditions

Urinary Bladder Neoplasms

Interventions

DRUG: TAR-200
BIOLOGICAL: Cetrelimab

Sponsor

Janssen Research & Development, LLC